Doses studied / as documented, not advice
Semaglutide dose and dosage, as the studies recorded them
The titration schedules, the oral and injectable routes, and the long half-life — reported exactly as the trials and labeling describe, never as a recommendation.
The gist
This page reports the Semaglutide dose figures exactly as they appear in the published trials and approved labeling. It is not advice, and it does not tell anyone what to take — dosing decisions belong to a prescriber.
In plain terms: semaglutide is usually started low and stepped up slowly over weeks, because going slowly is what keeps the stomach side effects manageable. The once-a-week shot is the most studied form. There is also a once-a-day pill, but the pill is absorbed poorly and has to be taken on an empty stomach with only a sip of water, well before anything else. The drug stays in the body a long time — about a week per dose — so it takes several weeks to fully clear after the last dose. All of the numbers below are tied to the study or label that recorded them.
Semaglutide dose: the subcutaneous titration schedule
The subcutaneous (under-the-skin) regimen is built around slow dose escalation, and the rationale is tolerability — stepping up gradually is how the trials kept gastrointestinal events, concentrated around titration, mostly mild-to-moderate and transient [8]. For chronic weight management, the documented schedule steps once-weekly from 0.25 mg in weeks 1–4, to 0.5 mg, to 1.0 mg, to 1.7 mg, reaching a 2.4 mg maintenance dose. STEP 1, the pivotal weight trial, used that 2.4 mg maintenance dose [1].
For type 2 diabetes, the documented subcutaneous schedule initiates at 0.25 mg once weekly and steps to 0.5 mg and then 1.0 mg maintenance, with a 2.0 mg option studied. SUSTAIN-6, the cardiovascular-outcomes trial, used the 0.5 mg and 1.0 mg doses [2], and FLOW, the kidney trial, used 1.0 mg [6]. These are the regimens as studied, not instructions.
Semaglutide dosage at the higher and investigational end
Beyond the standard maintenance dosage, the research record documents higher exposures. SURMOUNT-5 compared semaglutide 2.4 mg head-to-head against tirzepatide over 72 weeks [7]. On the oral side, obesity-research dosing has reached 25 mg and 50 mg once daily in dedicated trials. Investigational high-dose obesity work has studied a 7.2 mg once-weekly subcutaneous dose. These higher and investigational doses appear in the trial literature and are reported here as documented research dosing — they are not maintenance recommendations and not advice.
Oral semaglutide
Oral semaglutide is a once-daily tablet, and its dosing is dominated by an absorption problem. The tablet is co-formulated with an absorption enhancer called SNAC, which transiently raises the local stomach pH to help the peptide cross into the bloodstream; even so, oral bioavailability is only about 0.4–1% [20]. Because of that, the documented administration is strict: taken on an empty stomach, 30 minutes before the first food, drink or other oral medication, with no more than about 120 mL of water.
The documented oral type 2 diabetes schedule is 3 mg daily for 30 days, then 7 mg, then 14 mg daily. Higher oral doses of 25 mg and 50 mg have been studied for both diabetes (PIONEER PLUS) [10] and obesity. Administration errors — eating too soon, too much water — can substantially cut the absorbed dose and therefore the effect, which is why the fasted timing matters [20].
Semaglutide injection: route and storage
The semaglutide injection is given subcutaneously once weekly, the route used across the SUSTAIN, STEP, SELECT and FLOW programs [1][2][3][6]. As documented in the approved labeling, commercial pre-filled pens are typically stored refrigerated (2–8°C) before first use and may then be kept at room temperature (up to 30°C) for a defined in-use period commonly cited as up to 56 days. Reconstituted research preparations are generally kept at 2–8°C and used within about 28 days. The oral tablet, co-formulated with SNAC, is not reconstituted. None of this is administration guidance — it is the documented handling described in the labeling and research record.
Half-life and clearance
Semaglutide's elimination half-life is approximately one week — commonly cited as about 165–168 hours — for both the subcutaneous and oral forms, with effectively complete clearance roughly five weeks after the final dose. That long half-life is conferred by strong, reversible binding to albumin via the fatty-acid side chain, plus DPP-4 resistance from the position-8 substitution. The clearance arithmetic has a direct safety consequence: because the drug lingers for about five weeks after the last dose, label guidance advises stopping well in advance of a planned pregnancy [19]. A clinical pharmacokinetics study also found no clinically relevant effect on the levels of co-administered metformin, warfarin, atorvastatin or digoxin, consistent with a low drug-interaction risk [12].